Botulinum toxin: yesterday, today, tomorrow
Botulinum toxin (BoNT) is a bacterial neurotoxin presented with seven serotypes that inhibit neurotransmitter release from nerve endings. The serotypes of BoNT are antigenically dissimilar, act via different, but interconnected mechanisms, and are not interchangeable. The activity of BoNT is associa...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2015-02-01
|
| Series: | Нервно-мышечные болезни |
| Subjects: | |
| Online Access: | https://nmb.abvpress.ru/jour/article/view/44 |
| _version_ | 1797702086001950720 |
|---|---|
| author | A. R. Artemenko A. L. Kurenkov |
| author_facet | A. R. Artemenko A. L. Kurenkov |
| author_sort | A. R. Artemenko |
| collection | DOAJ |
| description | Botulinum toxin (BoNT) is a bacterial neurotoxin presented with seven serotypes that inhibit neurotransmitter release from nerve endings. The serotypes of BoNT are antigenically dissimilar, act via different, but interconnected mechanisms, and are not interchangeable. The activity of BoNT is associated with impaired neuroexocytosis occurring in several steps: from the binding of BoNT to its specific receptor on the axon terminal membrane to the proteolytic enzymatic cleavage of SNARE substrate. The effect of BoNT is considered to be restricted to the peripheral nervous system, but when given in particularly high doses, it has been recently shown to affect individual brain structures. In addition, by modulating peripheral afferentation, BoNT may influence the excitability of central neuronal structures at both spinal and cortical levels. Only BoNT serotypes A and B are used in clinical practice and aesthetic medicine. The type A has gained the widest acceptance as a therapeutic agent for more than 100 abnormalities manifesting themselves as muscular hyperactivity, hyperfunction of endocrine gland, and chronic pain. The effect of BoNT preparations shows itself 2-5 days after injection, lasts 3 months or more, and gradually decreases with as a result of pharmacokinetic and intracellular reparative processes. Biotechnology advances and potentialities allow purposefully modification of the protein molecular structure of BoNT, which expands the use and efficiency of performed therapy with neurotoxins. Recombinant technologies provide a combination of major therapeutic properties of each used BoNT serotype and expand indications for recombinant chimeric toxins. |
| first_indexed | 2024-03-12T04:45:06Z |
| format | Article |
| id | doaj.art-80ca259fa27947e88e42191dc2281fde |
| institution | Directory Open Access Journal |
| issn | 2222-8721 2413-0443 |
| language | Russian |
| last_indexed | 2024-03-12T04:45:06Z |
| publishDate | 2015-02-01 |
| publisher | ABV-press |
| record_format | Article |
| series | Нервно-мышечные болезни |
| spelling | doaj.art-80ca259fa27947e88e42191dc2281fde2023-09-03T09:28:59ZrusABV-pressНервно-мышечные болезни2222-87212413-04432015-02-010261910.17650/2222-8721-2013-0-2-6-1938Botulinum toxin: yesterday, today, tomorrowA. R. Artemenko0A. L. Kurenkov1ГБОУ ВПО Первый МГМУ им. И.М. СеченоваФГБУ «Научный центр здоровья детей» РАМН, МоскваBotulinum toxin (BoNT) is a bacterial neurotoxin presented with seven serotypes that inhibit neurotransmitter release from nerve endings. The serotypes of BoNT are antigenically dissimilar, act via different, but interconnected mechanisms, and are not interchangeable. The activity of BoNT is associated with impaired neuroexocytosis occurring in several steps: from the binding of BoNT to its specific receptor on the axon terminal membrane to the proteolytic enzymatic cleavage of SNARE substrate. The effect of BoNT is considered to be restricted to the peripheral nervous system, but when given in particularly high doses, it has been recently shown to affect individual brain structures. In addition, by modulating peripheral afferentation, BoNT may influence the excitability of central neuronal structures at both spinal and cortical levels. Only BoNT serotypes A and B are used in clinical practice and aesthetic medicine. The type A has gained the widest acceptance as a therapeutic agent for more than 100 abnormalities manifesting themselves as muscular hyperactivity, hyperfunction of endocrine gland, and chronic pain. The effect of BoNT preparations shows itself 2-5 days after injection, lasts 3 months or more, and gradually decreases with as a result of pharmacokinetic and intracellular reparative processes. Biotechnology advances and potentialities allow purposefully modification of the protein molecular structure of BoNT, which expands the use and efficiency of performed therapy with neurotoxins. Recombinant technologies provide a combination of major therapeutic properties of each used BoNT serotype and expand indications for recombinant chimeric toxins.https://nmb.abvpress.ru/jour/article/view/44ботулинический токсиннейротоксинсеротипы ботулинического токсинанарушение нервно-мышечной передачиацетилхолинsnap-25синтаксинсинаптобревинцентральная нервная системафокальные дистонииспастичностьхроническая больгипергидроз |
| spellingShingle | A. R. Artemenko A. L. Kurenkov Botulinum toxin: yesterday, today, tomorrow Нервно-мышечные болезни ботулинический токсин нейротоксин серотипы ботулинического токсина нарушение нервно-мышечной передачи ацетилхолин snap-25 синтаксин синаптобревин центральная нервная система фокальные дистонии спастичность хроническая боль гипергидроз |
| title | Botulinum toxin: yesterday, today, tomorrow |
| title_full | Botulinum toxin: yesterday, today, tomorrow |
| title_fullStr | Botulinum toxin: yesterday, today, tomorrow |
| title_full_unstemmed | Botulinum toxin: yesterday, today, tomorrow |
| title_short | Botulinum toxin: yesterday, today, tomorrow |
| title_sort | botulinum toxin yesterday today tomorrow |
| topic | ботулинический токсин нейротоксин серотипы ботулинического токсина нарушение нервно-мышечной передачи ацетилхолин snap-25 синтаксин синаптобревин центральная нервная система фокальные дистонии спастичность хроническая боль гипергидроз |
| url | https://nmb.abvpress.ru/jour/article/view/44 |
| work_keys_str_mv | AT arartemenko botulinumtoxinyesterdaytodaytomorrow AT alkurenkov botulinumtoxinyesterdaytodaytomorrow |